A 0,05% cyclosporine treatment of the advanced dry eye syndrome;Leczenie zaawansowanych przypadków zespołu suchego oka 0,05% roztworem cyklosporyny

Klinika Oczna

Volumn 107, Issue 4-6, 2005, Pages 280-286

  Kujawa, Agnieszka ^a,b   Rózycki, Radosław ^a  

^a Wojskowego Instytutu Medycznego   (Poland)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Cyclosporine; Dry eye syndrome; Sjogren's Syndrome; Tear films normalization

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; DRY EYE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; SCHIRMER TEST; SJOEGREN SYNDROME; TREATMENT DURATION; MIDDLE AGED; PATHOPHYSIOLOGY; TIME; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; BONE MARROW TRANSPLANTATION; CYCLOSPORINE; DRY EYE SYNDROMES; FEMALE; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; SJOGREN'S SYNDROME; TIME FACTORS; TREATMENT OUTCOME;

EID: 27244446499     PISSN: 00232157     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. McDonald M. B.: Changing paradigms in the diagnosis and treatment of dry eye. Leading ophthalmologists discuss Restasis, the first and only FDA-approved therapy for dry eye. A supplement to Eye World, 2003, VII, 3-15.
2. Perry H. D., Donnenfeld E. D.: Medications for dry eye syndrome: a drug-therapy review. A supplement to Managed Care, 2003, 12/12, 26-31.
3. Wilson S. E.: Inflammation: a unifying theory for the origin of dry eye syndrome. A supplement to Managed Care, 2003, 12/12, 14-19.
4. Sheppard J. D.: Guidelines for the treatment of chronic dry eye disease. A supplement to Managed Care, 2003, 12/12, 20-25.
5. Hirsch J. D.: Considerations in the pharmacoeconomics of dry eye. A supplement to Managed Care, 2003, 12/12, 33-38.
6. Pflugfelder S. C., Solomon A., Stern M. E.: The diagnosis and management of dry eye: a twenty-five years reviev. Cornea, 2000, 19, 644-649.
7. Sail K., Stevenson O. D., Mundorf T. K., Reis B. L: The CsA phase 3 study group. Two multicenter, randomized studies of the efficiacyand safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology, 2000, 107, 631-639.
8. Restasis. Broszura informacyjna doła̧czona do opakowania leku. Allergan Inc., 2002.
9. Goła̧b J., Jakóbisiak M., Lasek W.: Immunologia, wydanie nowe. (red.) Kruoyńska K., Wydawnictwo Naukowe PWN, Warszawa, 2002, 508-510.
10. Kervick G. N., Pflugfelder S. C., Haimovici R. et al.: Paracentral rheumatoid corneal ulceration. Clinical feaures and cyclosporine therapy. Ophthalmology, 1992, 99, 80-88.
11. Lipner M.: Restasis: Getting beyond the dry factors. Eye World, 2003, 36.
12. Gao J., Schwalb T. A., Addeo J. V.: The role of apoptosis in the pathogenesis of canine keratokonjunctivitis sicca: The effect of topical cyclosporine A therapy. Cornea, 1998, 17, 654-663.
13. Marsh P., Pflugfelder S. C.: Topical nonpreserved methyloprednisolone therapy for keratokonjunctivitis sicca in Sjogren's syndrome. Ophthalmology, 1999, 106, 811-816.
14. Baudouin C., Brignole F., Becquet F. et al.: Flow cytometry in impression cytology speciments. A new method for evaluation of conjunctival inflammation. Invest. Ophthalmol. Vis. Sci., 1997, 38, 1458-1467.
15. Stern M. E., Fox R. I., Gao J., Micreheff A. K., Pflugfelder S. C.: The pathology of dry eye: The interaction between the ocular surface and lacrimal glands. Cornea, 1998, 17, 584-589.
16. Tsubota K., Fujihara T., Saito K., Takeuchi T.: Conjunctival epithelium expression of HLA-DR in dry eye patients. Ophthalmologica, 1999, 213, 16-19.
17. Sheppard J. D.: Dry eye moves beyond palliative therapy. A supplements Managed Care, 2003, 12/12, 6-8.
18. Kaswan R. L., Salisbury M. A., Ward D. A.: Spontaneous canine keratoconjunctivitis sicca. A useful model for human keratoconjunctivitis sicca treatment with cyclosporine eye drops. Arch. Ophthalmol., 1989, 107, 1210-1216.
19. Perry H. D., Donnenfeld E. D.: Issues in the use of preservative free topicals. A supplement to Managed Care, 2003, 12/12, 39-41.
20. American Academy of Ophthalmology: Punctal oclusion for the dry eye: ophthalmic procedure assesment. Ophthalmology, 1997, 104, 1521-1524.
21. Stevenson D., Tauber J., Reis B. L.: Efficacy and safety of Cyclosporine A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. Ophthalmology, 2000, 107, 967-974.